Peptide Initiative

Peptides · Peptide comparison

Defensin (HBD-3) vs LL-37

Most potent human beta-defensin (45 amino acids) with unique salt-insensitive antimicrobial activity — kills MRSA at MIC 0.5-1.0 μg/mL regardless of salt concentration, disrupts biofilms at 4-8 μg/mL, and retains full bactericidal function even without its disulfide bonds — representing a next-generation antimicrobial peptide template for combating antibiotic resistance

Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeDefensin (HBD-3)200–200 mcg/mLLL-371.6–1.6 mg/mL
FrequencyDefensin (HBD-3)As neededLL-37Once daily
AdministrationDefensin (HBD-3)Topical application (research/wound care)LL-37Topical application (wound healing)
Cycle lengthDefensin (HBD-3)Ongoing/indefiniteLL-3712+ weeks
Onset speedDefensin (HBD-3)Rapid (hours to days)LL-37Moderate (1-2 weeks)
Evidence levelDefensin (HBD-3)Moderate human trials (Phase 1-2)LL-37Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Fighting Drug-Resistant Bacteria

Defensin (HBD-3)96%
LL-37No recorded rating

Wound Healing

Defensin (HBD-3)88%
LL-3794%

Immune System Support

Defensin (HBD-3)82%
LL-37No recorded rating

Fighting Infections

Defensin (HBD-3)No recorded rating
LL-3791%

Immune Boost

Defensin (HBD-3)No recorded rating
LL-3787%

Technical data

Compound specifications

Defensin (HBD-3)

Molecular formula
Approximately C220H340N64O62S6 (45-amino acid peptide with 3 disulfide bonds)
Molecular weight
~5,155 Da (mature peptide)
Half-life
Short systemic half-life (minutes) typical of cationic peptides; disulfide-bonded form provides protease resistance at local tissue sites; linear form shows adequate stability for topical applications
Bioavailability
Topical application achieves high local concentrations; maintains activity in physiological salt environments (unique); linear form retains activity enabling simplified formulation; not intended for oral or systemic delivery
CAS number
Not assigned (endogenous human peptide; research-grade available from peptide suppliers)

LL-37

Molecular formula
C205H340N60O53
Molecular weight
4,493.26 Da
Half-life
Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes
Bioavailability
Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery
CAS number
154947-66-7

Protocols

Dosing compared

Defensin (HBD-3)

Topical

  • 200 µg/mL applied to the wound, about 4 µg per dose (20 µL)Every 2 days in the study · Until wound healed (study setting)HBD-3 is a research-only peptide with no human dosing protocol. No published study gives a topical peptide dose: the infected-diabetic-wound study on this page delivered hBD-3 by gene transfer, not as an applied peptide [6], so this amount is unsourced. Human use has not been established.

LL-37

Topical

  • 0.5 mg/mL gelTwice weekly · 4 weeksLowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4].
  • 1.6 mg/mL gelTwice weekly · 4 weeksMid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4].

Applications

Best suited for

Defensin (HBD-3)

Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
Defensin (HBD-3) is particularly well-suited for individuals focused on research into anti-mrsa therapeutics and alternatives to vancomycin for resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of antimicrobial wound dressings and medical device coatings
Defensin (HBD-3) is particularly well-suited for individuals focused on development of antimicrobial wound dressings and medical device coatings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-biofilm strategies for chronic wound infections and implant-associated infections
Defensin (HBD-3) is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and implant-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Applications requiring antimicrobial activity in physiological or high-salt environments
Defensin (HBD-3) is particularly well-suited for individuals focused on applications requiring antimicrobial activity in physiological or high-salt environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

LL-37

Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3][5].
Anti-biofilm strategies for chronic wound infections and medical device-associated infections
LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Boosting innate immune defense in immunocompromised or aging individuals
LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2].

Safety profile

Side effects

Defensin (HBD-3)

Common

  • Local site irritation
  • Transient inflammatory response
  • Mild wound bed changes

Uncommon

  • Localized allergic reaction
  • Mild cytotoxicity at high concentrations

Serious

  • No serious adverse effects documented at therapeutic concentrations

LL-37

Common

  • Local site irritation
  • Transient stinging or burning
  • Mild perilesional erythema
  • Increased wound exudate

Uncommon

  • Allergic contact reaction

Serious

  • Hemolytic activity at systemic concentrations

Research status

Safety & evidence

Defensin (HBD-3)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Defensin HBD-3 is not FDA-approved and has no completed human clinical trials, existing only in research contexts with in vitro and animal study data. Animal toxicology studies demonstrate no major systemic toxicity at doses exceeding therapeutic levels, but human immunological responses to exogenously administered defensin peptides have not been characterized. Risks include potential immune activation, cross-reactivity with self-antigens (due to HBD-3 expression in healthy epithelial cells), development of anti-peptide antibodies, and possible tolerance development with repeated dosing. Bacterial and fungal resistance to defensin-based therapy is theoretically possible. No human pharmacokinetics, dose-ranging studies, Phase 1 safety assessments, or clinical efficacy data exist.

Contraindications

  • Known hypersensitivity to defensin peptides or formulation components
  • Pregnancy and breastfeeding — insufficient safety data for exogenous defensin administration
  • Active autoimmune conditions — potential for immune activation through monocyte/macrophage recruitment
  • Severe hepatic or renal impairment — peptide clearance may be altered for any systemic exposure

LL-37

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, [2] conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.

Contraindications

  • Known hypersensitivity to cathelicidin peptides or formulation components
  • Active hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity
  • Pregnancy and breastfeeding — insufficient reproductive safety data from clinical trials
  • Severe renal impairment — peptide clearance may be altered

Decision guide

Which is right for you?

Defensin (HBD-3)

Choose Defensin (HBD-3) if…

  • Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
  • Development of antimicrobial wound dressings and medical device coatings
  • Anti-biofilm strategies for chronic wound infections and implant-associated infections
  • Applications requiring antimicrobial activity in physiological or high-salt environments

LL-37

Choose LL-37 if…

  • Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
  • Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
  • Anti-biofilm strategies for chronic wound infections and medical device-associated infections
  • Boosting innate immune defense in immunocompromised or aging individuals